Abstract
BackgroundThe effect of moderately elevated blood glucose levels among non-diabetic subjects on cancer prognosis is not well described. The goal of this study was to examine the association of elevated random blood glucose (RBG) levels in non-diabetic breast cancer patients with overall survival (OS) and time to tumor recurrence (TTR).ResultsForty-nine deaths and 32 recurrences occurred among 148 eligible study subjects during 855.44 person-years of follow-up, with median follow-up of 5.97 years. We observed that patients with elevated RBG levels experienced significantly shorter OS (hazard ratio [HR], 3.01; 95 % confidence interval [CI] (1.70–5.33); P < 0.001) and shorter TTR (HR, 2.08; CI (1.04–4.16); P = 0.04) as compared to patients with non-elevated RBG levels. After controlling for tumor grade, tumor stage, race, and BMI, elevated RBG continued to display high and statistically significant association with shorter OS (HR, 3.50; CI (1.87–6.54); P < 0.001). Adjustment for age, race, and BMI strengthened HR of RBG for TTR. The association of RGB with TTR lost its borderline statistical significance upon controlling for both tumor grade and stage.ConclusionsThe data suggest that elevated blood glucose is associated with poor prognosis of breast cancer patients. Given the potential clinical implication, these findings warrant further investigation.
Highlights
The effect of moderately elevated blood glucose levels among non-diabetic subjects on cancer prognosis is not well described
We adopted random blood glucose (RBG) values of 120 mg/dL or higher to be an indication of disorders in glucose metabolism [22, 24], and performed a retrospective cohort study to evaluate the relationship between elevated blood glucose levels and survival of nondiabetic breast cancer subjects
We observed that elevated RBG levels correlate with poor prognosis in breast cancer patients independently of age, tumor characteristics, race, and body mass index (BMI)
Summary
The effect of moderately elevated blood glucose levels among non-diabetic subjects on cancer prognosis is not well described. The goal of this study was to examine the association of elevated random blood glucose (RBG) levels in non-diabetic breast cancer patients with overall survival (OS) and time to tumor recurrence (TTR). We adopted RBG values of 120 mg/dL or higher to be an indication of disorders in glucose metabolism [22, 24], and performed a retrospective cohort study to evaluate the relationship between elevated blood glucose levels and survival of nondiabetic breast cancer subjects. We observed that elevated RBG levels correlate with poor prognosis in breast cancer patients independently of age, tumor characteristics, race, and BMI
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
